chidamide + camrelizumab + apatinib

Chidamide + camrelizumab + apatinib is an investigational combination therapy comprising three agents with distinct mechanisms of action, evaluated primarily in oncology clinical trials. Chidamide is a selective oral histone deacetylase (HDAC) inhibitor that modulates gene expression and induces apoptosis in malignant cells. Camrelizumab is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance antitumor immune responses. Apatinib is a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis and tumor blood supply. This triple combination aims to synergistically target cancer cells through epigenetic modulation, immune activation, and antiangiogenic effects[1][2][4].